Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11617169 | 0.85 | LMNA (0.40) | GAAMAPK1MEN1KMT2AFAAH | |
| SCHEMBL24212836 | 0.82 | LMNA (0.43) | GAAMAPK1MEN1KMT2AFAAH | |
| SCHEMBL23743176 | 0.82 | MEN1 (0.50) | GAAMAPK1MEN1KMT2AFAAH | |
| SCHEMBL24212934 | 0.81 | FAAH (0.41) | GAAMAPK1MEN1KMT2AFAAH | |
| SCHEMBL26027039 | 0.80 | MAPK1 (0.39) | GAAMAPK1MEN1KMT2AFAAH | |
| SCHEMBL23342484 | 0.79 | MEN1 (0.47) | MAPK1MEN1KMT2AFAAHALDH1A1 | |
| SCHEMBL19010923 | 0.79 | KMT2A (0.59) | GAAMAPK1MEN1KMT2AFAAH | |
| SCHEMBL13164724 | 0.78 | LMNA (0.46) | GAAMAPK1MEN1KMT2AFAAH | |
| SCHEMBL24212536 | 0.78 | MEN1 (0.44) | GAAMAPK1MEN1KMT2AFAAH | |
| SCHEMBL27097551 | 0.78 | LMNA (0.38) | GAAMAPK1MEN1KMT2AFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200121684-A1 | MODULATORS OF BTK PROTEOLYSIS AND METHODS OF USE | UNIV YALE (US) | 2020-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200121684-A1 | MODULATORS OF BTK PROTEOLYSIS AND METHODS OF USE | BTK, CBL, CRBN | GAA 766/4885MAPK1 2521/4885MEN1 2657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.